Korin Miller
December 16, 2020, 1:28 PM
The foods you now eat can have an impact on your cognition down the road. And, according to the results of a new study, eating cheese and drinking red wine may actually give your brain a boost.
The study, which was published in the
Journal of Alzheimer’s Disease, analyzed data over a 10-year period from 1,787 people between the ages of 46 and 77 in the U.K. Biobank, a large-scale biomedical database and research resource. The researchers specifically looked at participants’ fluid intelligence test (FIT) which provides a snapshot of a person’s ability to think quickly when they started the study and again in two follow-up assessments. Researchers also analyzed their diet and alcohol consumption over time.
Vancouver, BC – December 21, 2020
BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”) announced today that further analysis of the data from a preclinical animal study (also known as the “murine model study”) of its haptenized viral protein vaccine technology show that BVX-0320, its Covid-19 vaccine candidate based on the Company’s haptenized viral protein platform, elicits a robust T-cell response against SARS-CoV-2.
Using a technique called flow cytometry, the BioVaxys team found that its haptenized SARS-CoV-2 s-spike vaccine activated CD4+ helper T cells and CD8+ killer T cells that express the activation markers, CD69 and CD25. This result indicates that immunization with BVX-0320 at two different dose levels of 3µg or 10µg stimulated immune system memory ‘helper’ T-cells as well as killer T cells. CD4
The second coronavirus vaccine was approved Friday and arrived Monday in central Ohio, where one of the first doses was administered at Mount Carmel St. Ann s Hospital.
Dr. Mark Herbert, an infectious disease specialist, was the health system s first frontline worker to be immunized just after 11 a.m. Monday. His shot, much like many others inside hospitals the past week, was met with applause from a handful of Mount Carmel leaders who watched.
Doctors and politicians have hailed the vaccine as the beginning of the end of the pandemic. After receiving his shot Monday, Herbert praised the work of scientists to bring COVID-19 vaccines to fruition in record time, but he said it will still be several months before the shots end the outbreak.
Share this article
VANCOUVER, British Columbia, Dec. 21, 2020 /CNW/ BioVaxys Technology Corp. (
CSE: BIOV, FRA:5LB, OTC:LMNGF) ( BioVaxys ) announced today that further analysis of the data from a preclinical animal study (also known as the murine model study ) of its haptenized viral protein vaccine technology show that BVX-0320, its COVID-19 vaccine candidate based on the Company s haptenized viral protein platform, elicits a robust T-cell response against SARS-CoV-2.
Using a technique called flow cytometry, the BioVaxys team found that its haptenized SARS-CoV-2 s-spike vaccine activated CD4+ helper T cells and CD8+ killer T cells that express the activation markers, CD69 and CD25. This result indicates that immunization with BVX-0320 at two different dose levels of 3µg or 10µg stimulated immune system memory helper T-cells as well as killer T cells. CD4
Date Time
Mindfulness Program Reduces Stress, Builds Resilience In Health Care Workers COLUMBUS, Ohio – A free, 8-week mindfulness program created by researchers at The Ohio State University Wexner Medical Center and The Ohio State University College of Medicine significantly reduced burnout and perceived stress for healthcare faculty and staff, while increasing resilience and work engagement in this large healthcare system, a new study found.
The study participants included 267 resident physicians, resident chaplains, attending physicians, medical center faculty, and hospital administrative/managerial clinical staff at Ohio State Wexner Medical Center who demonstrated significant 27% reduction in burnout after completing the Mindfulness in Motion (MIM) program.